April 29, 2021
RareiTi Co-Founder Wendy White has joined the board of ICORD, the International Collaboration on Rare Diseases and Orphan Drugs.
April 23, 2021
RareiTi CEO Alex Evans, RN, has become a director of the Rare Disease Nurse Network (RDNN).
April 14, 2021
Technology-enabled, data-driven Managed Access company RareiTi is pleased to announce that Heather Manna has joined the company as Director of Regulatory Affairs.
April 8, 2021
Technology-enabled, data-driven Managed Access company RareiTi is delighted to make public its Advisory Board.
October 27, 2020
Technology enabled, data-driven Managed Access company RareiTi is delighted to announce the appointment of Dr. Olivia Kessel as Chief Medical Officer.
June 17, 2020
RareiTi Inc.™, the global technology-enabled Managed Access company welcomes Alex Evans, as Chief Executive Officer (CEO).
January 9, 2020
Wendy White and Natalie Douglas have known each other for years; Wendy was running Siren Interactive and Natalie was running IDIS and they would often find themselves working on the same compounds in the rare disease space.
January 9, 2019 / PharmaVoice.com
Wendy White is a passionate and innovative leader working at the intersection of advocacy, technology, and business in the rare disease space.
Imagine how different this journey would be if rare patients and caregivers had someone to talk to about it. Managing life with a rare disease involves a level of uncertainty. How do you create and stick to a treatment plan that is achievable?
The COVID-19 pandemic is having significant impact on clinical trials globally. Many trials face suspension or closure due to clinical priorities and the impact of social distancing and quarantine.
Clinical trial patients with a rare condition face great challenges; being part of a clinical trial when living with a rare condition can often be the only lifeline available, offering the chance to access novel therapies that could improve life enormously. During the pandemic, not being able to access novel therapies could have a major negative impact on health, disease progression and mortality. In addition, progress toward an approved therapy should not have to be completely stalled because of a lack of ability to collect relevant data.